Supportive care in severe and very severe aplastic anemia

Bone Marrow Transplantation

Volumn 48, Issue 2, 2013, Pages 168-173

  Schrezenmeier, H ^a   Hochsmann B ^a   Moicean, A ^b   Risitano, A ^c   Ljungman, P ^d  

^a UNIVERSITY OF ULM   (Germany)

^b FUNDENI CLINICAL INSTITUTE   (Romania)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

aplastic anemia; hematopoietic growth factors; infection; supportive treatment; transfusion

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CIPROFLOXACIN; COLISTIN; CYCLOSPORIN; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; NEOMYCIN; OSELTAMIVIR; PLACEBO; POSACONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THYMOCYTE ANTIBODY; VORICONAZOLE; ZANAMIVIR;

ALLOIMMUNIZATION; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL THERAPY; APLASTIC ANEMIA; ASPERGILLOSIS; BLOOD TRANSFUSION; CHELATION THERAPY; CYTOPENIA; DECISION MAKING; DISEASE SEVERITY; FEBRILE NEUTROPENIA; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE SEPSIS; HAND WASHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFLUENZA; IRON CHELATION; IRON OVERLOAD; MORTALITY; MYCOSIS; NEUTROPENIA; NEUTROPHIL COUNT; PATIENT MOBILITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SOCIAL SUPPORT; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; VACCINATION; VIRUS INFECTION; VIRUS REACTIVATION;

ANEMIA, APLASTIC; BLOOD TRANSFUSION; HUMANS; PALLIATIVE CARE; PLATELET TRANSFUSION; PROGNOSIS; TREATMENT OUTCOME;

EID: 84873480756     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.220     Document Type: Review

References (80)

1. Passweg JR, Marsh JC. Aplastic anemia: First-line treatment by immunosuppression and sibling marrow transplantation. Hematology (Am Soc Hematol Educ Program) 2010; 2010: 36-42
2. Valdez JM, Scheinberg P, Nunez O, Wu CO, Young NS, Walsh TJ. Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis 2011; 52: 726-735
3. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011; 365: 430-438
4. Tichelli A, Schrezenmeier H, Socie G, Marsh J, Bacigalupo A, Duhrsen U et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: A study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood 2011; 117: 4434-4441
5. Teramura M, Kimura A, Iwase S, Yonemura Y, Nakao S, Urabe A et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: A multicenter randomized study in Japan. Blood 2007; 110: 1756-1761
6. Valdez JM, Scheinberg P, Young NS, Walsh TJ. Infections in patients with aplastic anemia. Semin Hematol 2009; 46: 269-276
7. Weinberger M, Elattar I, Marshall D, Steinberg SM, Redner RL, Young NS et al. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore) 1992; 71: 24-43
8. Bacigalupo A, Brand R, Oneto R, Bruno B, Socie G, Passweg J et al. Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy-The European Group for Blood and Marrow Transplantation experience. Semin Hematol 2000; 37: 69-80
9. Gafter-Gvili A, Ram R, Raanani P, Shpilberg O. Management of aplastic anemia: The role of systematic reviews and meta-analyses. Acta Haematol 2011; 125: 47-54
10. Gafter-Gvili A, Fraser A, Paul M, van de Wetering M, Kremer L, Leibovici L. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane. Database. Syst Rev 2005; 19: CD004386
11. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142: 979-995
12. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: Systematic review and meta-analysis. J Antimicrob Chemother 2007; 59: 5-22
13. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Antibiotic prophylaxis in neutropenic patients. Isr. Med Assoc J 2007; 9: 460-462
14. Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A et al. Antibiotic prophylaxis in neutropenic patients: New evidence, practical decisions. Cancer 2006; 107: 1743-1751
15. Schlesinger A, Paul M, Gafter-Gvili A, Rubinovitch B, Leibovici L. Infection-control interventions for cancer patients after chemotherapy: A systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 97-107
16. van TF, Harbers MM, Terporten PH, van Boxtel RT, Kessels AG, Voss GB et al. Normal hospital and low-bacterial diet in patients with cytopenia after intensive chemotherapy for hematological malignancy: A study of safety. Ann Oncol 2007; 18: 1080-1084
17. Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol 2008; 26: 5684-5688
18. Moody K, Finlay J, Mancuso C, Charlson M. Feasibility and safety of a pilot randomized trial of infection rate: Neutropenic diet versus standard food safety guidelines. J Pediatr Hematol Oncol 2006; 28: 126-133
19. DeMille D, Deming P, Lupinacci P, Jacobs LA. The effect of the neutropenic diet in the outpatient setting: A pilot study. Oncol Nurs Forum 2006; 33: 337-343
20. Jubelirer SJ. The benefit of the neutropenic diet: Fact or fiction? Oncologist 2011; 16: 704-707
21. U.S Department of Agriculture. Food safety of people with cancer 2011, 20-3- 2012
22. Mattner F, Bange FC, Meyer E, Seifert H, Wichelhaus TA, Chaberny IF. Preventing the spread of multidrug-resistant gram-negative pathogens: Recommendations of an expert panel of the german society for hygiene and microbiology. Dtsch Arztebl Int 2012; 109: 39-45
23. Gould D. Nurses' hand decontamination practice: Results of a local study. J Hosp Infect 1994; 28: 15-30
24. Hayes-Lattin B, Leis JF, Maziarz RT. Isolation in the allogeneic transplant environment: How protective is it? Bone Marrow Transplant 2005; 36: 373-381
25. Khan SA, Wingard Jr. Infection and mucosal injury in cancer treatment. J Natl Cancer Inst Monogr 2001; 29: 31-36
26. Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: Systematic review and meta-analysis. J Clin Oncol 2007; 25: 5471-5489
27. Wingard JR, Eldjerou L, Leather H. Use of antibacterial prophylaxis in patients with chemotherapy-induced neutropenia. Curr Opin Hematol 2012; 19: 21-26
28. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biol Blood Marrow Transplant 2009; 15: 1143-1238
29. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Wu CO, Young NS. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood 2012; 119: 345-354
30. Marsh JC, Socie G, Schrezenmeier H, Tichelli A, Gluckman E, Ljungman P et al. Haemopoietic growth factors in aplastic anaemia: A cautionary note. European Bone Marrow Transplant Working Party for Severe Aplastic Anaemia. Lancet 1994; 344: 172-173
31. Gurion R, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, Yeshurun M et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica 2009; 94: 712-719
32. Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009; 147: 43-70
33. Marsh JC, Ganser A, Stadler M. Hematopoietic growth factors in the treatment of acquired bone marrow failure states. Semin Hematol 2007; 44: 138-147
34. Gluckman E, Rokicka-Milewska R, Hann I, Nikiforakis E, Tavakoli F, Cohen-Scali S et al. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol 2002; 119: 1075-1082
35. Socie G, Mary JY, Schrezenmeier H, Marsh J, Bacigalupo A, Locasciulli A et al. Granulocyte-stimulating factor and severe aplastic anemia: A survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007; 109: 2794-2796
36. Ohara A, Kojima S, Hamajima N, Tsuchida M, Imashuku S, Ohta S et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997; 90: 1009-1013
37. Quillen K, Wong E, Scheinberg P, Young NS, Walsh TJ, Wu CO et al. Granulocyte transfusions in severe aplastic anemia: An eleven-year experience. Haematologica 2009; 94: 1661-1668
38. Ljungman P, Small TN. Vaccination of SCT recipients. Bone Marrow Transplant 2011; 46: 621
39. Jeong SH, Lee HS. Hepatitis A: Clinical manifestations and management. Intervirology 2010; 53: 15-19
40. Viallard JF, Boiron JM, Parrens M, Moreau JF, Ranchin V, Reiffers J et al. Severe pancytopenia triggered by recombinant hepatitis B vaccine. Br J Haematol 2000; 110: 230-233
41. Hendry CL, Sivakumaran M, Marsh JC, Gordon-Smith EC. Relapse of severe aplastic anaemia after influenza immunization. Br J Haematol 2002; 119: 283-284
42. Bengtsson C, Kapetanovic MC, Kallberg H, Sverdrup B, Nordmark B, Klareskog L et al. Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: Results from the Swedish EIRA study. Ann Rheum Dis 2010; 69: 1831-1833
43. Salemi S, D'Amelio R. Are anti-infectious vaccinations safe and effective in patients with autoimmunity? Int Rev Immunol 2010; 29: 270-314
44. Champlin RE, Horowitz MM, van Bekkum DW, Camitta BM, Elfenbein GE, Gale RP et al. Graft failure following bone marrow transplantation for severe aplastic anemia: Risk factors and treatment results. Blood 1989; 73: 606-613
45. Piccin A, O'Marcaigh A, Smith O, O'Riordan J, Crowley M, Vandenberg E et al. Outcome of bone marrow transplantation in acquired and inherited aplastic anaemia in the Republic of Ireland. Ir J Med Sci 2005; 174: 13-19
46. Hernandez-Boluda JC, Marin P, Carreras E, Aguilar JL, Granena A, Rozman C et al. Bone marrow transplantation for severe aplastic anemia: The Barcelona Hospital Clinic experience. Haematologica 1999; 84: 26-31
47. Killick SB, Win N, Marsh JC, Kaye T, Yandle A, Humphries C et al. Pilot study of HLA alloimmunization after transfusion with pre- storage leucodepleted blood products in aplastic anaemia. Br J Haematol 1997; 97: 677-684
48. Desmarets M, Cadwell CM, Peterson KR, Neades R, Zimring JC. Minor histocompatibility antigens on transfused leukoreduced units of red blood cells induce bone marrow transplant rejection in a mouse model. Blood 2009; 114: 2315-2322
49. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861-1869
50. Dzik WH. Leukoreduction of blood components. Curr Opin Hematol 2002; 9: 521-526
51. The 2009 Annual Short Report (2010). Taylor, C, Cohen, H, Mold, D, Jones, HobotSHoTSSG (eds.). 2010
52. Kaminski ER, Hows JM, Goldman JM, Batchelor Jr. Pretransfused patients with severe aplastic anaemia exhibit high numbers of cytotoxic T lymphocyte precursors probably directed at non-HLA antigens. Br J Haematol 1990; 76: 401-405
53. German Association of Physicians. Cross-sectional guidelines for therapy with blood components and plasma derivatives. Transfus Med Hemother 2009; 36: 347-481
54. Sagmeister M, Oec L, Gmur J. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood 1999; 93: 3124-3126
55. Höchsmann B, Seidel H, Wiesneth M, Schrezenmeier H. Is the low platelet transfusion trigger in the new cross-sectional German guidelines of risk in outpatient setting? Prophylactic platelet transfusions in aplastic anemia. Transfus Med Hemother 2010; 36: 38
56. Schrezenmeier H, Seifried E. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: Which product type should be preferred? Vox Sang 2010; 99: 1-15
57. Laundy GJ, Bradley BA, Rees BM, Younie M, Hows JM. Incidence and specificity of HLA antibodies in multitransfused patients with acquired aplastic anemia. Transfusion 2004; 44: 814-825
58. Bean MA, Graham T, Appelbaum FR, Deeg HJ, Schuening F, Sale GE et al. Gammairradiation of pretransplant blood transfusions from unrelated donors prevents sensitization to minor histocompatibility antigens on dog leukocyte antigenidentical canine marrow grafts. Transplantation 1994; 57: 423-426
59. Marsh J, Socie G, Tichelli A, Schrezenmeier H, Hochsmann B, Risitano AM et al. Should irradiated blood products be given routinely to all patients with aplastic anaemia undergoing immunosuppressive therapy with antithymocyte globulin (ATG)? A survey from the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Br J Haematol 2010; 150: 377-379
60. Fast LD, DiLeone G, Marschner S. Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation. Transfusion 2011; 51: 1397-1404
61. Vamvakas EC. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev 2005; 19: 181-199
62. Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ, Meyers JD. Use of leukocytedepleted platelets and cytomegalovirus- seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 78: 246-250
63. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant [see comments]. Blood 1995; 86: 3598-3603
64. Nichols WG, Price TH, Gooley T, Corey L, Boeckh M. Transfusion- transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003; 101: 4195-4200
65. Paphilon DH, Rider JR, Barbara JA, Williamson LM. Prevention of transfusiontransmitted cytomegalovirus infection. Transfus Med 1999; 9: 115-123
66. Lee JW. Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: A review of experience in South Korea. Int J Hematol 2008; 88: 16-23
67. Kim KH, Kim JW, Rhee JY, Kim MK, Kim BS, Kim I et al. Cost analysis of iron-related complications in a single institute. Korean J Intern Med 2009; 24: 33-36
68. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001; 1: 47-61
69. Takatoku M, Uchiyama T, Okamoto S, Kanakura Y, Sawada K, Tomonaga M et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007; 78: 487-494
70. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586-4588
71. Pullarkat V, Blanchard S, Tegtmeier B, Dagis A, Patane K, Ito J et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008; 42: 799-805
72. Koreth J, Antin JH. Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation. Haematologica 2010; 95: 364-366
73. Deeg HJ, Spaulding E, Shulman HM. Iron overload, hematopoietic cell transplantation, and graft-versus-host disease. Leuk Lymphoma 2009; 50: 1566-1572
74. Gattermann N. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk Res 2007; 31(Suppl 3): S10-S15
75. Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 2008; 88: 24-29
76. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: New data, new questions. Blood 2006; 107: 3436-3441
77. Park SJ, Han CW. Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis. J Korean Med Sci 2008; 23: 320-323
78. Mwanda OW, Otieno CF, Abdalla FK. Transfusion haemosiderosis inspite of regular use of desferrioxamine: Case report. East Afr Med J 2004; 81: 326-328
79. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M et al. Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010; 95: 557-566
80. Lee JW, Yoon SS, Shen ZX, Ganser A, Hsu HC, Habr D et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: A subgroup analysis of 116 patients from the EPIC trial. Blood 2010; 116: 2448-2454